The median age of the patients was 46.2 years (range 24–86), 63% had HR-positive/ HER2−negative BC, 24% had HER2-positive disease and 11% had triple-negative breast cancer (TNBC). Here, ERBB2 is linked to triple-negative breast carcinoma.